Program
cysteamine-pantetheine disulfide
Also written as “TTI-0102”, “TTI-0102 (cysteamine-pantetheine disulfide)” and “TTI-0102: cysteamine-pantetheine disulfide”.
Its studies are mostly in Cystinosis · MELAS Syndrome · Leigh Disease · COVID-19, led by Thiogenesis Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Thiogenesis Therapeutics | 42 open or running | phase 2since Jan 26, 2022 | Jan 26, 2022 | Dec 2026phase 2 · NCT07837726 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 26, 2022First study: phase 2 study in COVID-19First studyNCT05212662
- Sep 29, 2024Phase 2 study in MELAS SyndromeNCT06644534 · 9 enrolled · France, Netherlands
- May 6, 2025Phase 2 study in Leigh DiseaseNCT06990984 · 18 planned
- Sep 13, 2026Phase 2 study in CystinosisNCT07837726 · 6 planned
Ahead
- Dec 2026Primary completion: phase 2 study in CystinosisNCT07837726
- Jun 2027Primary completion: phase 2 study in Leigh DiseaseNCT06990984
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07837726Cystinosis | 2 | Not yet recruiting | Dec 2026 | 6 |
| NCT06990984Leigh Disease | 2 | Not yet recruiting | Jun 2027 | 18 |
| NCT06644534MELAS Syndrome · France, Netherlands | 2 | Completed | Jan 12, 2026 | 9 |
| NCT05212662COVID-19 | 2 | Withdrawn | Sep 27, 2024 | 0 |
How it is read
Names in the registry
- “TTI-0102”, 2 entries
- “TTI-0102 (cysteamine-pantetheine disulfide)”, 1 entry
- “TTI-0102: cysteamine-pantetheine disulfide”, 1 entry
Conditions, from the studies’ own filings
- Cystinosis, 1 study
- MELAS Syndrome, 1 study
- Leigh Disease, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.